BioMarin Pharmaceutical, Inc. has entered into an agreement to acquire Repligen’s histone deacetylase inhibitor (HDACi) library and related intellectual property. The HDACi portfolio includes preclinical compounds with potential applications in Friedreich’s ataxia and other neurological disorders. Repligen will receive an upfront payment of $2 million and potential future milestone and royalties for the development, regulatory approval and commercialization of compounds included in t...